Key points from article :
Development of therapeutics that slow the degenerative processes associated with aging and improve functional outcomes in patients suffering from age-related diseases, by Biophytis.
The major milestones in the development of Sarconeos (BIO101)- results of the SARA-INT Phase 2 study as well as the outline of SARA Phase 3 study, orally presented by Drs. Waly Dioh.
Sarconeos (BIO101) has the potential to be the first drug candidate ever moving into Phase 3 in Sarcopenia.
The duration of this study is estimated at 36 months from the inclusion of the first patient expected at the end of 2022.
Stanislas Veillet, CEO of Biophytis, states: "No drug is currently approved for sarcopenia in the world ... the first company to initiate a Phase 3 program."
The development of Sarconeos (BIO101) for the treatment of sarcopenia held at the 15th International SCWD Congress (Society on Sarcopenia, Cachexia & Wasting disorders).
